Bing

SEARCH HISTORY

Stepping back, the stock now sits at a year-to-date loss of 37.8%. Meanwhile, calls remain the options of choice in DNDN's options pits. The stock's Schaeffer's put/call open interest ratio (SOIR) of 0.50 ranks higher than just 22% of other such readings ...
Minyanville · 8/23/2013
Dendreon Corporation (DNDN) was one of the Russell 2000's biggest losers for August 12 as the stock slid 33.96% to $1.40, a loss of $0.72 per share. Starting at an opening price of $1.67 a share, the stock traded between $1.33 and $1.73 over the course of ...
Stockhouse · 8/13/2014
Dendreon Corporation (NASDAQ:DNDN) was the most active in the industry, adding 6.80% to close at $6.91 after analyst actions. Sanford C. Bernstein analysts upgraded and lifted their PT on the stock claiming that Provenge is projected to have a 10% to …
The Real Edge Magazine · 2/11/2013
More from Bing News
A large number of biotech stocks have been clearing healthy bases recently. While each stock has an individual story related to a drug or product, their strong performance as a group shows that investors have been willing to put money to work in riskier ...
Investopedia · 3/8/2010
Dendreon Corp (NASDAQ: DNDN) shares have spiraled high just before trade was halted at 12:34 pm EST. The stock made a jump on a Fox Business report of the FDA approving Dendreon’s PROVENGE as a late-stage treatment for prostate cancer.
Benzinga · ByMonica Gerson · 4/29/2010
The Small Cap Network (smallcapnetwork.com), a leading online investment community focused on small cap stocks, has issued an analysis of biotech stocks Dendreon Corp.(DNDN), Novavax, Inc.(NVAX), and Anadys Pharmaceuticals Inc. (ANDS) …
TransWorldNews · 4/27/2009
DNDN is trading up 0.75% at $5.38 on Thursday. The stock has been trading between $3.69 and $17.04 for the past 52 weeks. Hampton Roads Bankshares (HMPR) Names Interim Finance Chief Apollo Group (APOL) Unit Receives Contract From Advanced …
istock Analyst · 12/20/2012
StockCall.com Provides Stock Research on ACADIA Pharmaceuticals Inc., Dendreon ... ACAD), Dendreon Corporation (NASDAQ: DNDN), Medivation Inc. (NASDAQ: MDVN), Cell Therapeutics Inc. (NASDAQ: CTIC), and Sarepta Therapeutics Inc.
4 Traders · 6/13/2013
And so far, bears seem to be sitting pretty, as the stock has declined by 35% year to date. So let's take a closer look at two reasons why Wall Street is so bearish on this small-cap biotech. DNDN data by YCharts Reason No. 1 Dendreon's prostate cancer ...
The Motley Fool · 6/7/2014
And can I just say? Is Dendreon a giant magnet for high drama and intrigue or what? This time I'm talking about the freakish, steep selloff in shares of DNDN that occurred within about a two-minute span before the stock got halted for trading around 1:30p ...
CNBC · 4/29/2009